Saturday 17 October 2026
Export GRI’s income statement to Excel — free account
GRI Bio, Inc.
In the quarter to June 2026, EPS grew 97.5% and free cash flow grew 54.3%, each against the same quarter a year earlier.
1.38
0.02
−1.43%
Follow GRI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 4,691,123.00 | 266,393.41 | 13,861.12 | 143.75 | 6.10 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 13,462,613.00 | 10,915,632.00 | 1,598,360.38 | 30,940.00 | 437.92 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 3 | 2 | 4 | 4 | 4 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (4) | (3) | (5) | (9) | (3) | (13) | (8) | (12) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | (4,822.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (4) | (3) | (5) | (9) | (3) | (13) | (8) | (12) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (19.00) | (0.98) | (1.07) | (1.42) | (898,257.30) | (140,562.80) | (1,546.50) | (121.80) | |||||
| Cash flow | — | — | (10.44) | (0.81) | (0.82) | (1.27) | 0.00 | (89,900.00) | (1,324.77) | (103.73) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (80.00) | 0.00 | (0.03) | |||||
| Free cash flow | — | — | (10.44) | (0.81) | (0.82) | (1.27) | 0.00 | (89,980.00) | (1,324.77) | (103.76) | |||||
| Book value | — | — | 0.67 | 0.91 | (0.32) | 0.89 | 0.00 | 2,590.00 | 620.31 | 61.18 | |||||
| Shares, m | — | — | 0 | 4 | 5 | 7 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (11,875,144.94) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (3) | (4) | (8) | (1) | (9) | (9) | (10) | ||||
| Capex | — | — | 0 | — | 0 | — | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | (2) | (3) | (4) | (8) | (1) | (9) | (9) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 3 | (2) | 6 | (2) | 0 | 4 | 6 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | — | — | — | — | |||||
| Net debt | — | — | (1) | (4) | 0 | (8) | 0 | (2) | (5) | (8) | |||||
| Shareholders’ equity | — | — | 0 | 3 | (1) | 6 | (2) | 0 | 4 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (1,349.37) | (140.95) | (184.36) | (200.28) | (73.80) | (780.89) | (232.73) | (166.00) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | (256.19) | (205.77) | (547.95) | (426.35) | (153.45) | 1,908.78 | (471.59) | (238.17) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Mar 2020
Charts ten years each
GRI Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $3.2M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $3.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARAV ARAVIVE, INC | $3.0M | — (loss-making) | — (loss-making) | −44.39% (below 0%: shrinking) | n/m | +48.19% (above 0%: growing) | 100.00% | (323.44%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.9M | 0.0× | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| Median of peers | $3.1M | — | — | −64.50% | — | −19.01% | 27.32% | 0.00% |
GRI Bio, Inc. (GRI) key facts
- GRI Bio, Inc. (GRI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GRI traded at $1.38, a market capitalization of $3.1 million.
- Return on equity was −238.2% and debt-to-equity 0.00.